Olorinab

DB14998InvestigationalSmall molecule

Olorinab is under investigation in clinical trial NCT03155945 (Tolerability, Pharmacokinetics, and Efficacy of APD371 in Subjects With Crohn's Disease Experiencing Abdominal Pain).

Mechanism: Pharmacologically active on Cannabinoid receptor 2
Curator reviewed
Formula / weight: C₁₈H₂₃N₅O₃ · 357.414 g/mol (avg)
Code names: APD371

Resolves to

Compound

UNII581F7DFA9BCAS1268881-20-4

Structure

InChIKeyACSQLTBPYZSGBA-GMXVVIOVSA-NSMILESCC(C)(C)[C@@H](CO)NC(=O)C1=NN(C2=C1C[C@@H]1C[C@H]21)C1=C[N+]([O-])=CC=N1

Targets

P34972CNR2

What you can answer from here — as of June 15, 2026

1Protein targetEach mapped to UniProt, with action and pharmacological action

Listed above

3Clinical trialsPhase, status and sponsor resolved per trial

2+ReferencesStructured and connected to the statements they support

Which drugs share a target with Olorinab, and which of those have an active Phase 3 trial?

Answer this in Biopharma OS Sign in to your account

Create a free account or log in to explore the full data card.

Create Account